Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spare kids with leukemia from painful bone marrow needles

NCT ID NCT07483476

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study looks at whether a simple blood test can track how well treatment is working in children with acute lymphoblastic leukemia (ALL). Currently, doctors must take bone marrow samples to check for leftover cancer cells, which is invasive and painful. The researchers will compare DNA from blood samples with DNA from bone marrow to see if the blood test is just as accurate. If it works, it could mean fewer bone marrow biopsies for children undergoing leukemia treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a less invasive way to monitor leukemia in children, using a simple blood test instead of repeated bone marrow biopsies.
What could go wrong
This is an early observational study, not a treatment trial. It may find that blood tests are not accurate enough to replace bone marrow biopsies, or that results vary too much between patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 205 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population Children and adolescents with newly diagnosed acute lymphoblastic leukemia treated in participating pediatric hematology centers, as well as healthy pediatric siblings undergoing HLA typing.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: ALL population * Age \< 18 years * Newly diagnosed B-cell or T-cell acute lymphoblastic leukemia * Absence of BCR::ABL1 rearrangement * For infants (\<12 months), absence of KMT2A rearrangement * Inclusion before initiation of corticosteroid therapy or chemotherapy * Written informed consent from legal guardians * Affiliation to a national health insurance system Control population * Age \< 18 years * Undergoing blood sampling for HLA typing in the context of bone marrow donor evaluation * Sibling of a patient with leukemia * Written informed consent from legal guardians * Affiliation to a national health insurance system Exclusion Criteria: * Pregnant or breastfeeding patients * Patients not affiliated with a health insurance system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia (ALL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Neoplasm, Residual Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukemia (ALL)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Armand Trousseau

    RECRUITING

    Paris, France

  • Hôpital Robert Debré

    RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.